The National Institute for Health and Care Excellence (NICE) has published draft recommendations aimed at integrating emerging blood-based biomarkers into diagnostic pathways for early Alzheimer’s disease, the agency announced today. The draft guidance sets out how validated blood tests could be used alongside clinical assessment to improve early identification of people at risk of progressive cognitive decline.
Scope and proposed pathway changes from NICE
Under the draft proposals, blood-based biomarker tests that meet the agency’s validation criteria would be offered to patients presenting with cognitive symptoms as part of a stepped diagnostic approach. NICE outlines that such tests could be used to triage patients for more specialist assessment and advanced imaging, potentially reducing delays in diagnosis and focusing resources on those most likely to have underlying neurodegenerative pathology.
Evidence appraisal and next steps
NICE emphasised that the recommendations are conditional on robust evidence of analytical and clinical validity. The agency will continue its appraisal process over the coming weeks, inviting comment from clinicians, researchers and patient groups before finalising guidance. Stakeholders are asked to submit evidence on comparative accuracy, impact on clinical decision-making, and cost-effectiveness.
The draft guidance highlights the potential role of biomarkers in primary and secondary care settings and recommends implementation pilots where feasible. NICE also flags the need for clear commissioning frameworks to ensure equitable access and appropriate follow-up for patients receiving positive test results.
Implications for UK clinical practice
If adopted, the guidance could accelerate the integration of blood-based diagnostics into memory services across the UK, supporting earlier identification and management of patients with mild cognitive impairment or early Alzheimer’s disease. Clinicians welcomed the focus on evidence-based introduction but cautioned that training and capacity in memory clinics would need reinforcing to manage potential increases in referrals.
NICE’s consultation will run for several weeks, after which the organisation will review responses and publish final guidance. The draft document aims to balance the promise of emerging diagnostics with the requirement for rigorous validation before routine clinical use.
For the draft guidance and consultation details, see the NICE website: NICE.
Sursa foto: AI-generated image
